Idiopathic Pulmonary Fibrosis Phase 3 Trial: 60 mg Wins
Idiopathic pulmonary fibrosis Phase 3 trial: admilparant 60 mg met its FVC goal in 1,255 patients, but 120 mg missed. What is known and what is not.
Idiopathic pulmonary fibrosis Phase 3 trial: admilparant 60 mg met its FVC goal in 1,255 patients, but 120 mg missed. What is known and what is not.